At the news
? NEUTRALIMPACT 4/10 6-K filed Nov 13, 2026 at 06:10 ET
GSK announced that the EMA's CHMP has issued a positive opinion recommending a label update for Bexsero (4CMenB) to include a single booster dose for individuals aged 10+ previously vaccinated at least two years earlier. The recommendation is based on Phase IIIb data showing immune memory established in infancy can be boosted up to 19 years later. This is a regulatory milestone that could expand Bexsero's addressable adolescent booster market in Europe if adopted by the European Commission.
- CHMP recommended updating Bexsero label to include a single booster dose for individuals aged 10 years and older previously vaccinated at least two years earlier
- Recommendation based on Phase IIIb study Men-B-096 (312 participants) which met its primary endpoint
- Bexsero is registered in 61 countries, included in 15 national/regional infant immunization programs and 3 adolescent programs in Europe
- Around 140 million doses of Bexsero distributed globally since 2015
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access